BCL-2 Expression Predicts Radiotherapy Failure in Laryngeal Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6602647
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Cortactin Expression Predicts Poor Survival in Laryngeal Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2008English

The Expression of BCL-2 and BID in Gastric Cancer Cells

Journal of Immunology Research
MedicineAllergyImmunology
2014English

Neoadjuvant Chemotherapy Followed by Radiotherapy for Laryngeal Cancer

Journal of Biomedicine
2016English

Expression of Glycoconjugates in Laryngeal Cancer

Journal of Otolaryngology of Japan
Otorhinolaryngology
1995English

Expression of BCL-2 in Breast Cancer: Correlation With Clinicopathological Characteristics and Survival

Acta medica (Hradec Kralove)
Medicine
2008English

Evaluation of BCL-2 Expression in Cigarette Smokers

Egyptian Dental Journal
2017English

Downregulation of BCL-2 Expression in Lymphoma Cells by BCL-2 ARE-targeted Modified, Synthetic Ribozyme

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2003English

Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histological Grading

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy